Complement activation and the resulting inflammatory response is an important potential mechanism for multisystem organ injury in cardiac surgery. Novel therapeutic strategies using complement inhibitors may hold promise for improving outcomes for cardiac surgical patients by attenuating complement activation or its biologically active effector molecules. Recent clinical trials evaluating complement inhibitors have provided important data to further delineate the impact of complement activation and its inhibition on clinical outcomes. In this review we examine the role of complement activation and its inhibition as a therapeutic approach in cardiac surgery. (Anesth Analg 2012;115:759 -71) T he complement system comprises Ͼ30 serum proteins that interact in a precise series of enzymatic cleavage and membrane binding events that lead to the generation of products with immunoprotective, immunoregulatory, and proinflammatory activities. Complement activation is associated with inflammatory injury in a heterogeneous group of clinical settings including cardiac surgery. Multiple pathways are responsible for complement activation in cardiac surgery including bioincompatibility of the cardiopulmonary bypass (CPB) circuit, reversal of heparinization, and activation via tissue ischemia and reperfusion. Recent advances in biotechnology and the development of complement inhibitors have allowed clinicians to examine the impact of inhibiting complement activation on clinical outcomes in cardiac surgery. This review will describe the complement system, mechanisms of activation, role of complement in inflammation and ischemia/reperfusion injury, and current therapeutic strategies for attenuating complement activation or its biologically active components in cardiac surgical patients.
THE COMPLEMENT SYSTEM Complement System Activation Pathways
The complement cascade comprises one of the main effector arms of both antibody-dependent and -independent mediated immunity. Complement was first identified as a heat-labile substance in serum that "complemented" antibodies in killing bacteria. 1, 2 The complement system serves as a bridge between innate and adaptive immunity in not only defending against bacterial infection, but also in disposing of both immune complexes and the products of inflammatory injury. 1, 2 The 30 plasma and cell surface proteins of the complement system together amount to Ͼ3 g/L of plasma and make up nearly 15% of the globulin fraction. 2 Activation occurs in a sequential manner with proteolytic cleavage of complement components yielding enzymatically active molecules that function as biological mediators and produce further downstream component activation. Understanding the sequence of complement activation is important because there are multiple therapeutic targets, which may attenuate its activation or antagonize biologically active metabolites. 3 Three pathways of complement system activation have been described and include the classical, the alternative, and the mannose-binding lectin pathways ( Fig. 1 and Table  1 ). The classical pathway of complement activation is initiated when antibody-antigen complexes (immunoglobulin [IgG] or IgM) interact with the first complement component, C1. This protein in turn consists of a C1q component and 2 molecules each of the serine proteases, C1r and C1s. C1q binds to the Fc moiety of immune complexes to activate C1r and C1s. Subsequent cleavage of C2 and C4 leads to the generation of the classical pathway C3 convertase (i.e., C4b2a). In contrast to the classical pathway, the alternative pathway is activated by multiple mechanisms including bacterial products (endotoxin, exotoxin), yeast cell walls (zymosan), biomaterials (CPB and hemodialysis tubing), tissue type plasminogen activator, and the continuous interaction of C3 with water, which forms a C3b-like molecule known as C3H 2 O. The rate-limiting step of alternative pathway activation is the enzymatic cleavage of factor B by factor D to form the alternative pathway C3 convertase (i.e., C3bBb). The final pathway of complement activation, the lectin pathway, is primarily an antibody-independent pathway activated by binding of mannose-binding lectin (also known as mannan/ mannose-binding lectin/protein; MBL), as well as binding of ficolins or collectin 11 (CL-K1), to carbohydrate structures present on the surface of bacteria, yeast, parasitic protozoa, and viruses. 4, 5 Associated with mannose-binding lectin are mannose-binding lectin associated serine proteases (MASP)-1/3 and MASP-2, serine proteases that cleave C2 and C4 to form the classical complement pathway C3 convertase. Mannose-binding lectin is structurally related to C1q, whereas MASP-1 and MASP-2 display remarkable homology to the classical pathway serine proteases, C1r and C1s. 6 A bypass pathway involving complement activation by the mannose-binding lectin complex, in the absence of C2 and C4, has also been described and involves alternative pathway activation by MASP-1/3. [7] [8] [9] [10] All 3 complement activation pathways converge at C3, which is cleaved into C3a and C3b. C3a is a weak anaphylatoxin that is rapidly inactivated to C3a-des-arg by serum proteases. Attachment of C3b to either of the C3 convertases converts them into a C5 convertase, which can cleave C5 into C5a and C5b. C5a is a potent anaphylotoxin and induces alterations in smooth muscle and vascular tone and increases vascular permeability. 11 Finally, C6, C7, C8, and multiple C9 molecules can be assembled to C5b and forms C5b-9, called the membrane attack complex or terminal complement complex, which is involved in host defense and cellular injury. C3a, iC3b, C5a, and C5b-9 are the most studied biologically active complement components and are considered the major complement mediators involved in inflammatory injury. 3 
Regulation of the Complement System
Complement activation is highly regulated by both plasma and integral membrane-bound proteins. Complement receptor type 1 (CR1;CD35) and membrane cofactor protein (MCP;CD46) are integral membrane proteins, while decay type accelerating factor (DAF;CD55) and CD59 are bound to the cell membrane phospholipid domain via a glycophosphatidylinositol anchor and can thus be easily cleaved by phospholipase C. CR1/CD35 plays a major role in opsonization of C3b-bound immune-complex leading to their clearance. Furthermore, MCP/CD46 acts as a cofactor for factor I-mediated cleavage of C3b and C4b. DAF/CD55 prevents the assembly of both alternative and classical pathway C3 convertases 12, 13 and accelerates their decay by promoting dissociation of C2b from C4b2a or Bb from C3bBb. 14 Thus, DAF/CD55, CR1/CD35, and MCP/CD46 inhibit complement activation at the level of C3. On the other hand, CD59 is a 20 kDa glycoprotein that interacts with both C8 and C9 during C5b-9 assembly to limit C9 insertion into the cell membrane. 15, 16 Additional protective mechanisms for nucleated cells against activated complement components include membrane attack complex internalization through endocytosis or ejection by exocytosis. 17, 18 Complement activation is further regulated by multiple humoral and membrane-based control mechanisms. The humoral or fluid-phase proteins involved in complement regulation include C1-inhibitor (C1INH), C4-binding protein (C4-bp), properdin, carboxypeptidase N (CPN), S-protein, clusterin, and factors H and I. 19 -21 C1-inhibitor prevents excessive amplification of the classical pathway by covalently interacting with C1s and C1r, while still allowing free C1q to interact with its receptors. 22 The classical complement pathway is also regulated by C4binding protein, which binds the C3 convertase, C4b2a, and accelerates its decay by dissociating C2a. 23 Factor H accelerates the decay of the alternative complement pathway C3 convertase. Finally, factor I is a serine protease, which regulates the classical and alternative complement pathway C3/C5 convertases by inactivating C4b and C3b by cleaving the C3b and C4b ␣-chains. 24 Interestingly, properdin, which has historically been thought to stabilize the C3 convertase, promotes factor B binding to C3b and increases C3 convertase activity. 25 
Complement Modulation of Inflammation
Complement modulates vascular homeostasis and contributes to inflammatory injury through multiple mechanisms ( Table 2 ). Complement activation generates proinflammatory mediators and amplifies injury via activated C5 and C3, leading to the release of peptides that serve as ligands for specific receptors on polymorphonuclear leukocytes, monocytes, macrophages, mast cells, and other cells. Biologically active products of C3 and C5 cleavage include C3a/C3a des Arg, C5a/C5a des Arg, iC3b, and C5b-9. 3, 26 C5a is 1000-fold more potent than C3a as an inflammatory mediator and maintains biologic activity in the des Arg form, whereas C3a des Arg is without inflammatory activity. C5a also serves as the primary chemotactic factor for circulating neutrophils. C5a increases neutrophil adhesion to endothelium by mobilizing internal stores of neutrophil complement receptor 1, CD11b/CD18, CD62P, and CD11c. 27, 28 Furthermore, C5a exacerbates tissue injury and inflammation by binding to neutrophils causing activation, aggregation, and subsequent release of oxygen-free radicals, proteolytic enzymes, and arachidonic acid metabolites. 29 Finally, C5a facilitates the generation of chemokines, cytokines, and other proinflammatory mediators. 30, 31 C5 inhibition decreases neutrophil adhesion and transmigration, even though iC3b deposition still occurs in vivo. [32] [33] [34] C5 inhibition also decreases expression of inflammatory molecules after ischemia/reperfusion injury. 32, 33, 35 C3a interacts mainly with eosinophils, implicating C3a involvement in allergic inflammation. 36, 37 Even though iC3b, formed after C3b cleavage, is a specific ligand for neutrophil adhesion via CD11b/CD18 in vitro, 38 iC3b formation in vivo does not support neutrophil adhesion in the presence of C5 inhibition. 32, 33, 39 Thus, the specific role of iC3b as an in vivo ligand for neutrophil adhesion is not yet clearly defined.
Another important complement component, the membrane attack complex C5b-9, activates endothelial nuclear factor-B (NF-B) to increase leukocyte adhesion molecule transcription and expression. 40 Moreover, this complex can lead to direct lysis of anucleated cells (e.g., bacteria and red blood cells). Endothelial leukocyte adhesion molecules influenced by complement activation include vascular cell adhesion molecule-1, 41,42 intercellular adhesion molecule-1, and E-selectin. 43 C5b-9 increases surface expression of P-selectin on platelets and endothelial cells from internal stores to increase neutrophil adhesion. 15, 44 C5b-9 also promotes leukocyte activation and chemotaxis by inducing endothelial interleukin-8 and monocyte chemoattractant protein-1 secretion. 31 Furthermore, C5b-9 alters vascular tone by interfering with nitric oxide-mediated relaxation and decreasing endothelial cyclic guanosine monophosphate. 42, 45 Multiple "hits" result in pore formation leading to ion fluxes, cell swelling, and cellular activation Sublytic deposition triggers neutrophil production and release of reactive oxygen species, proteolytic enzymes, leukotriene B 4 , prostaglandin E 2 , and thromboxane
PATHOPHYSIOLOGY OF COMPLEMENT ACTIVATION AND ITS IMPLICATIONS FOR THE CARDIAC SURGICAL PATIENT C1 Inhibitor Deficiency and Hereditary Angioedema
Hereditary angioedema is a syndrome in which complement is activated by tissue injury during surgery or stress and characterized by excessive edema of the mucosa of the intestine and the larynx. 46 The syndrome is primarily an autosomal dominant inherited disease that results in an inadequate level of C1 inhibitor that normally functions to inactivate serine esterases C1r and C1s, kallikrein of the kinin system, and activated factors XI and XII of the coagulation system. Plasmin degrades C1 inhibitor, and is an important trigger of angioedema. Excess bradykinin in the absence of C1 inhibitor is formed from the unregulated cleavage of high-molecular-weight kininogen by kallikrein. 47 In type 1 hereditary angioedema, that accounts for 85% of cases in which C1 inhibitor levels are decreased, whereas in type 2 46 hereditary angioedema, defective synthesis of C1 inhibitor results in normal C1 inhibitor levels but a dysfunctional protein. 46 Another important, but rare, type of angioedema associated with C1 inhibitor deficiency is caused by the presence of autoantibodies against the protein. The latter syndrome usually occurs in elderly persons and is often associated with a lymphoproliferative disease (i.e., B cell lymphomas). 48 Management of these patients for cardiac and other surgical procedures include addition of plasma-derived C1 inhibitor and the use of antifibrinolytics. 49, 50 In the future management of patients with hereditary angioedema may also include the use of recombinant human C1 inhibitor, which in addition to raising C1 inhibitor levels, binds and inactivates mannosebinding lectin and may give additional anti-inflammatory actions above those observed using plasma-derived C1 inhibitor. 51 
Cardiac Surgery and Complement Activation
Complement activation is triggered by multiple mechanisms during cardiac surgery, including the direct binding of C1q and mannose-binding lectin, [52] [53] [54] [55] or indirectly by binding to natural antibodies 5, 56, 57 or C-reactive protein (e.g., binding C1q). 58 During CPB, direct adsorption of C3 onto the artificial surface of the extracorporeal surface may promote alternative pathway activation. 59, 60 However, in comparison with studies investigating the interaction of complement with biologic membranes, less is known regarding the factors initiating and controlling complement activation on artificial surfaces. Nonetheless, biomaterials have been developed to ameliorate excessive complement activation associated with extracorporeal circulation. 61, 62 Complement activation during cardiac surgery may also develop via non-CPB-mediated mechanisms. 63, 64 For example, plasmin, produced as part of contact activation initiated by tissue injury, has been implicated in complement activation via direction activation of C3. 65 Also, protamine reversal of heparinization activates the classical complement pathway and inhibits plasma carboxypeptidase N. 66, 67 Plasma carboxypeptidase N inhibition results in more inflammation from increased anaphylatoxin and kinin concentration. The magnitude of complement activation during cardiac surgery correlates with postoperative pulmonary shunting induced by classical complement pathway activation by protamine-heparin complexes. 55 In addition, C4d-C-reactive protein, a marker for C-reactive protein-mediated complement activation, correlates with postoperative arrhythmias after coronary artery bypass graft (CABG). 68 Thus, complement can be activated by multiple mechanisms during cardiac surgery, and may be associated with significant perioperative morbidity.
Complement Activation and Perioperative Myocardial Ischemia/Reperfusion Injury
The etiology of myocardial dysfunction after cardiac surgery is multifactorial. 69 The myocardium may be particularly susceptible to ischemia during cardiac surgery due to underlying coronary artery disease, perioperative hemodynamic instability, inadequate protection during aortic cross-clamping and cardioplegic arrest, coronary artery embolization, or technical complications (i.e., incomplete revascularization, graft spasm, or other nonphysiologic bloodflow). Although prolonged myocardial ischemia alone jeopardizes cellular structural and biochemical integrity, oxygen deprivation that is limited to Ͻ20 minutes is usually associated with only transiently depressed myocardial contractility. 70 Paradoxically, the restoration of bloodflow after sustained myocardial ischemia results in a phenomenon known as myocardial ischemia/reperfusion injury, in which tissue injury is enhanced above that produced by ischemia alone.
Perioperative myocardial ischemia/reperfusion injury involves high-energy phosphate depletion, the generation of reactive oxygen species (ROS) upon the restoration of oxygen (O 2 ) delivery, and alterations in intracellular calcium (Ca 2ϩ ) homeostasis. In addition, the activation of several proinflammatory pathways-including the coagulation, cytokine, and complement cascades-can exacerbate tissue injury and functional impairment initiated by the original ischemic insult. 71 Thus, myocardial ischemia/reperfusion injury involves a complex pathophysiological process, which significantly contributes to perioperative cardiac dysfunction and associated morbidity.
Activated complement components can contribute to myocardial ischemia/reperfusion injury via both indirect effects of anaphylatoxins and direct effects of C5b-9, which may modify leukocyte responses, alter vascular homeostasis, lead to cellular activation, and ultimately induce tissue damage. Reperfusion exacerbates myocardial injury by activating complement, but complement activation may also be initiated during ischemia. 72 During ischemia, disruption of myocyte membrane integrity may allow intracellular entry and complement activation, resulting in inflammation and tissue injury. 19 Exposed basement membranes, subcellular organelles, mitochondrial particles, cardiolipin, certain sensitizing antibodies, or the coagulation/fibrinolytic system may directly activate complement. [73] [74] [75] Complement activation plays an important early role in modifying myocardial injury not just during ischemia but also during the early phases of reperfusion of the ischemic myocardium. Activated complement components (e.g., anaphylatoxins, C5b-9) modify ROS production and Ca 2ϩ flux, which contribute to ischemia/reperfusion injury. For example, ROS generation is directly promoted via C5ainduced conversion of xanthine dehydrogenase and xanthine oxidase in endothelial cells. 76 Ca 2ϩ influx is also facilitated by complement activation via formation and membrane insertion of C5b-9. 77, 78 Activated complement components are particularly important facilitators of endothelial cell -leukocyte interactions that alter vascular homeostasis. The anaphylatoxins C3a, C5a, and C4a act directly on smooth muscle to promote vasodilatation. 79 -81 C5a independently promotes neutrophil chemotaxis, aggregation and the production of ROS, and arachidonic acid metabolites. 82 Intracoronary C5a also promotes coronary vasoconstriction via thromboxane production from polymorphonuclear leukocytes-platelet interactions. [83] [84] [85] [86] [87] C5a modifies neutrophil adherence to endothelium by eliciting the release of platelet-activating factor, which subsequently activates neutrophils, upregulates ␤2-integrins, and induces l-selectin shedding. 19, 88 Furthermore, C5a may amplify the inflammatory response by inducing cytokine production. 19 Additionally, iC3b functions as a specific ligand for sustaining leukocyte adhesion to the vascular endothelium via ␤2-integrins 89 and facilitates the oxidative burst and release of proteolytic enzymes during neutrophil phagocytosis. 90, 91 C5b-9 modifies neutrophil-endothelial cell interactions by stimulating production of endothelial von Willebrand factor and rapid translocation of P-selectin from Weibel-Palade bodies to the endothelial surface. 92 Endothelial NF-B activation by C5b-9 increases leukocyte adhesion molecule transcription and expression. 43, 93 C5b-9 also alters vascular tone by inhibiting endotheliumdependent relaxation and decreasing endothelial cyclic guanosine monophosphate. 45, 93 Finally, C5b-9 promotes leukocyte activation and chemotaxis and triggers neutrophils to release ROS, proteolytic enzymes, and arachidonic acid metabolites (leukotriene B 4 , prostaglandin E2, thromboxane). 31, 94, 95 Inhibition of many of these individual actions induced by complement protects the vasculature and tissues from inflammation and injury, and helps to maintain homeostasis. Thus, complement activation appears to be an "upstream" inducer of many proinflammatory and vascular dysfunction processes.
Complement activation associated with myocardial ischemia/reperfusion injury may also result from activation of the lectin complement pathway after binding of mannosebinding lectin to cell surface structures. 5,56,96 -99 Although mannose-binding lectin does not normally recognize the body's own tissues, oxidative stress may alter cell surface membrane glycosylation, leading to increased mannosebinding lectin deposition. 72, 98, 100, 101 Thus, complement activation through any of the 3 delineated pathways may significantly contribute to the pathogenesis of myocardial ischemia/reperfusion injury.
GENETICS OF COMPLEMENT ACTIVATION AND ITS IMPLICATIONS FOR CARDIOVASCULAR DISEASE AND ADVERSE PERIOPERATIVE OUTCOMES
Inflammation has evolved over time to become a crucial component of an organism's immune response to pathogenic threats from microbial invasion or tissue injury.
Anesthesia and surgery are also associated with a dramatically increased inflammatory response with concurrent suppression of cell-mediated immunity, which may play a role in short-and long-term perioperative morbidity and mortality. [102] [103] [104] [105] [106] [107] Although perioperative systemic inflammation is universal, there is significant individual variation in the humoral response and associated perioperative morbidity. Consequently, sources of individual variation in the frequency and severity of postoperative adverse outcomes may be attributed not only to environmental but also genetic influences.
Polymorphisms of several inflammatory genes, including those responsible for components of the complement cascade, are associated with differences in corresponding plasma protein levels and related cardiovascular disorders among nonsurgical populations. For example, mannosebinding lectin deficiency is associated with increased risk of various infections, 108 increased incidence of sepsis and mortality in patients with systemic inflammatory response, 109 and severe atherosclerosis. 110 -112 Despite well-described associations between variations in genetic allotype, phenotypic expression, and the role of inflammation in cardiovascular disease, [113] [114] [115] there is little information available about patients undergoing cardiac surgical procedures. Nonetheless, several inflammatory gene polymorphisms have been identified that correlate with perioperative differences in plasma protein levels and adverse clinical outcomes. 116 Allotypic variation of certain complement genes is associated with significant variability in the production of activated complement components and adverse clinical outcomes. The C4 gene is coded at 2 different loci, resulting in 2 major products designated C4A and C4B (which are distinguished from the activated complement product C4a). 117 Activated C4A binds to immune complexes, whereas activated C4B has more affinity for erythrocyte membranes. 55, 118 Therefore, patients with the homozygous C4 null phenotype and lacking the C4A isotype of C4 may have decreased clearance of activated C4-bound heparin--protamine complexes. For example, pediatric cardiac surgical patients, homozygous for the C4A null phenotype, have increased C3a and C4a levels, decreased lung compliance during CPB, 119 and an increased risk for developing capillary leak syndrome. 120 Consequently, prolonged circulation times for heparin-protamine complexes leads to further complement activation and anaphylatoxin generation. Heterozygosity of C4A null phenotype among adult patients undergoing cardiac surgery requiring CPB is also associated with increased complement activation induced by heparin-protamine complexes and greater pulmonary shunt fractions. 55 Mannose-binding lectin deficiency is associated with arterial thrombosis in systemic lupus erythematosus among patients with variant alleles, 121 and early venous bypass graft occlusion after CABG, suggesting a potential common genetic linkage among inflammation, hypercoagulability, and adverse perioperative cardiovascular outcomes. 122 However, median mannose-binding lectin levels between occlusion and nonocclusion groups were not significantly different, thus complicating data interpretation in this underpowered study. 122 In contrast, mannose-binding lectin complexes have thrombin-like activity that mediates increased coagulation in vitro and in vivo in animal models. [123] [124] [125] Therefore, clinical studies on mannose-binding lectin deficiency and coagulation interactions are clearly warranted.
Although historically, complement activation as a component of perioperative systemic inflammation has been attributed to environmental factors, recent evidence has identified an important role of genetic influences on adverse clinical outcomes. 126 -130 In a prospective, longitudinal multi-institutional study of 978 patients undergoing primary CABG-only surgery with CPB, inclusion of the combined MBL2 LYQA secretor haplotype improved prediction models for perioperative myocardial injury on the basis of traditional risk factors alone. 128 In the near future, genotyping and phenotypic evaluation of inflammatory genes, including those responsible for complement components, may be included among current multivariate models of perioperative clinical risk assessment to help identify optimal interventional, anti-inflammatory, and immunomodulatory therapy, predict outcome, and improve patient care.
COMPLEMENT INHIBITION AS A THERAPEUTIC STRATEGY IN CARDIAC SURGERY
Multiple methods of inhibiting complement activation to reduce organ injury in cardiac surgical patients have been studied both experimentally and clinically (Table 3) . Several recently published clinical trials involving large numbers of cardiac surgical patients have further supported the role of complement inhibition as a potential therapeutic strategy. 131 The data from the clinical studies is discussed.
Plasma-Derived Complement Inhibitors
C1INH forms a complex with C1 (C1s and C1r) to inhibit C1 and components of the contact system proteases, including factors XIIa, XIa and kallikrein, as well as the lectin complement pathway. [132] [133] [134] [135] Cardioprotective effects of C1INH in myocardial ischemia/reperfusion injury is demonstrated in animal models. 136 -138 C1INH decreases infarct size and inflammation after myocardial ischemia/ reperfusion in cats 136 and pigs in comparison with controls. 137, 138 In a small clinical study, C1INH preserved hemodynamic performance and resulted in lower serum troponin levels in comparison with placebotreated patients undergoing CABG. 139 C1INH was used as "rescue therapy" for the treatment of myocardial ischemia/reperfusion injury in patients who became hemodynamically unstable after failed percutaneous transluminal angioplasty and required emergency surgical revascularization. 140 Hemodynamic stabilization, weaning of aortic counterpulsation, and withdrawal of inotropic support were achieved within 1 day after the initiation of C1INH treatment. In addition to plasmaderived C1INH, a recombinant form of human C1INH (Ruconest™/Rhucin®; Pharming, Leiden, The Netherlands) has been developed and approved for hereditary angioedema in Europe (not yet approved in the USA). The recombinant form of human C1INH also binds and inhibits mannose-binding lectin, suggesting that this form of C1INH may have additional advantages over plasma-derived C1INH. 51 Pexelizumab Pexelizumab (Alexion Pharmaceuticals, Inc., Cheshire, CT; Procter & Gamble, Cincinnati, OH) is a recombinant single chain, monoclonal antibody that binds to C5 to inhibit C5a and C5b-9 formation. Early preclinical studies demonstrated that pexelizumab significantly inhibited C5 cleavage and both neutrophil and platelet activation in an in vitro CPB circuit. 61 A subsequent phase IIa trial evaluated 35 adult cardiac surgical patients receiving 0, 0.2, 0.5, 1, or 2 mg/kg of pexelizumab. Pexelizumab was well tolerated and was associated with a dose-dependent inhibition of C5 cleavage. Furthermore, dosing at 1 or 2 mg/kg decreased CD11b expression on polymorphonuclear leukocytes or monocytes, and significantly reduced cumulative CK-MB release and new visuospatial deficits. 141 Finally, in a 914patient, double-blind, placebo-controlled, 65-center study of patients undergoing CABG, pexelizumab had no significant effect on overall cognition. However, when domainspecific effects were examined, a decline of at least 10% in the visuospatial domain was observed on postoperative day 4 in 56% of patients receiving placebo in comparison with 40% receiving pexelizumab by bolus and infusion (P ϭ 0.003). Similarly, on postoperative day 30, a 10% decline was present in 21% of patients in the placebo group versus only 12% of the drug bolus plus infusion group (P ϭ 0.016). 142 On the basis of these encouraging findings a doubleblind, placebo-controlled, prospective and randomized phase IIb clinical study was subsequently performed in 914 cardiac surgical patients stratified into 2 groups: CABGonly requiring CPB and CABG with concomitant valve surgery on CPB. 141 Patients were treated with placebo, pexelizumab 2.0 mg/kg bolus, or pexelizumab 2.0 mg/kg bolus followed by a 24-hour infusion at 0.05 mg/kg/hr. The patients were followed for 30 days to evaluate the safety and efficacy (CK-MB Ͼ 60 ng/mL; Q-wave myocardial infarction [MI]; new central neurological system deficit, left ventricular dysfunction; death; or a composite of death, MI, left ventricular dysfunction or new central neurological system deficit) of this intervention. Approximately 90% of the patients were in the CABG-only group (n ϭ 796). Pexelizumab was well tolerated and significantly inhibited complement activation (e.g., inhibition of hemolytic activity and decreased serum C5b-9 concentration) for 24 hours. There was no significant treatment effect of pexelizumab in comparison with placebo on the primary composite endpoint. Post hoc subgroup analysis, though, demonstrated that pexelizumab bolus plus infusion reduced the frequency of non-Q wave MI (when increasing the definition from a CK-MB Ͼ 60 ng/mL to 100 ng/mL) by 66% (2.7% vs 7.8%; P ϭ 0.01). Furthermore, the subgroup analysis found a reduction in the composite endpoint of death or MI (CK-MB Ͼ 100 ng/mL independent of Q-wave) with pexelizumab bolus plus infusion (but not bolus dosing alone) in comparison with placebo on postoperative day 30 (3% vs 9%; P ϭ 0.004). Adverse events and infections were not significantly increased in pexelizumab versus placebo-treated patients. The composite incidence of death or MI (Q-wave or non-Q-wave) was 7.8% versus 13.2% of placebo patients at 30 days and was not risk adjusted. However, these preliminary data supported a potential therapeutic role for complement inhibition in the attenuation of non-Q wave MI and perhaps mortality after cardiac surgery and provided the rationale for subsequent larger clinical studies. 141 In 2004, a larger phase III clinical trial called "Pexelizumab for Reduction in Infarction and Mortality in Coronary Artery Bypass Graft Surgery 1 (PRIMO-CABG)" evaluated the efficacy and safety of pexelizumab in reducing perioperative MI and mortality in CABG surgery. 143 The study was a prospectively randomized, double-blind, placebo-controlled trial, involving 3099 adult patients undergoing CABG surgery with or without valve surgery. Patients were randomly assigned to receive IV pexelizumab (2.0 mg/kg bolus plus 0.05 mg/kg per hour for 24 hours; n ϭ 1553) or placebo (n ϭ 1546) before CPB initiation. The primary composite endpoint was the incidence of death or MI (CK-MB Ͼ 100 ng/mL by postoperative day 4 independent of Q-wave; CK-MB Ͼ 70 ng/mL by postoperative day 4 with Q-wave; new Q-wave by postoperative day 30 that was not present of postoperative day 4; MI with or without Q-wave evidence identified by the investigator and confirmed by a Clinical Events Committee by postoperative day 30) within 30 days of randomization in those undergoing CABG surgery only (n ϭ 2746). Secondary analyses included the intent-to-treat analyses of the composite of death or MI at postoperative days 4 and 30 in all 3099 study patients. After 30 days, 134 (9.8%) of 1373 of patients receiving pexelizumab versus 161 (11.8%) of 1359 of patients receiving placebo died or experienced MI in the CABG-surgery-only population (relative risk, 0.82; 95% confidence interval [CI], 0.66 -1.02; P ϭ 0.07). In the intent-to-treat analyses, 178 (11.5%) of 1547 patients receiving pexelizumab versus 215 (14.0%) of 1535 receiving placebo died or experienced MI (relative risk, 0.82; 95% CI, 0.68 -0.99; P ϭ 0.03) but were not risk adjusted, and the trial was not powered to detect a reduction in mortality alone. In the CABG-surgery-only group, pexelizumab was not associated with a significant reduction in the risk of the composite endpoint of death or MI in the 2746 patients evaluted with nonrisk-adjusted data. However, in riskadjusted analysis, pexelizumab was associated with a statistically significant risk reduction in death or MI through postoperative day 30 among all 3099 patients undergoing CABG with or without valve surgery and provided the rationale for a larger clinical study of higher-risk patients.
As a result of the risk-adjusted data, an additional PRIMO-CABG II trial was undertaken as a prospectively randomized, double-blind, placebo-controlled trial, that enrolled 4254 patients undergoing CABG with or without valve surgery. The primary composite endpoint was the incidence of death or MI (defined as in PRIMO-CABG I) within 30 days of surgery. PRIMO-CABG II did not meet the primary composite endpoint of death or MI with 30 days of randomization (16.3% for placebo versus 15.2% for pexelizumab; P ϭ 0.20). 144 However, a retrospective analysis of the combined results of PRIMO-CABG I and II (n ϭ 7353) was performed, and the results were stratified by subsetting the patient populations according to their Society of Thoracic Surgery composite risk as opposed to their "PRIMO" risk, which was simply defined as the number of risk factors. On the basis of this analysis, death at 30 days was significantly reduced for the greatest risk subset (n ϭ 2156, pexelizumab 5.7% versus placebo 8.1%, P ϭ 0.024). Furthermore, this mortality reduction persisted throughout the 180-day follow-up period (pexelizumab 11.1% versus placebo 14.4%, non-risk adjusted, P ϭ 0.036). 144 The difference in PRIMO-CABG I and II trials may be a mortality benefit for high-risk patients. 144 
Soluble Complement Receptor Type 1
Soluble complement receptor type 1 (TP10) is a recombinant soluble complement receptor type 1 (sCR1) antagonist that inhibits complement activation by accelerating the decay of C3 and C5 convertases and by acting as a cofactor in the proteolytic degradation of C3b and C4b by factor I. 145 The sCR1 attenuates tissue injury in animal models related to ischemia/reperfusion injury, experimental CPB, and transplantation. 146 -148 Several prospective studies have evaluated TP10 in patients undergoing cardiac surgery. In infants Ͻ1 year of age undergoing CPB (n ϭ 15), TP10 was administered in a phase I/II open-label prospective trial at a dose of 10 mg/kg before CPB, and 10 mg per 100 mL prime volume added to the CPB circuit. 149 All infants survived without TP10-related adverse events. C3a was lower 12 hours after CPB in comparison with baseline pre-CPB levels and remained lower 24 hours after CPB. TP10 concentration inversely correlated with the 12-hour post-CPB to pre-CPB ratio of C3a and with total fluid, net fluid, and blood product administration per kilogram, through 24 hours after CPB. TP10 plasma concentration decreased to Յ60 g/mL 12 hours after CPB. On the basis of these findings, an initial dose of 10 mg/kg over 0.5 hour followed by an infusion of 10 mg/kg over 23.5 hours should maintain TP10 concentrations 100 to 160 g/mL for 24 hours after CPB. 149 A prospective, randomized, placebo-controlled, parallelgroup, phase II trial involving 594 high-risk, adult cardiac surgical patients requiring CPB evaluated the safety and efficacy of TP10. 150 After anesthesia induction, patients were assigned to 1 of 5 groups consisting of TP10 administrated as a bolus (0, 1, 3, 5, or 10 mg/kg) CPB. 150 The primary endpoint was the composite of death, MI, prolonged (Ն24 hours) intra-aortic balloon pump support, and prolonged tracheal intubation. TP10 significantly inhibited complement activity within 10 to 15 minutes of administration, an effect that persisted for 3 days postoperatively. Adverse events and infections were not significantly increased in TP10 versus placebo-treated patients. There was no difference in the primary endpoint between patients receiving TP10 in any dose versus placebo (31.4% TP10 vs 33.7% placebo; P ϭ 0.31). In subgroup analysis, however, the primary endpoint was reduced in male patients receiving TP10 ϫ 30% (35.4% in placebo to 24.6% for TP10; P ϭ 0.026), and included a 36% reduction in death and MI (26.8% for placebo versus 17.1% for TP10; P ϭ 0.025). In contrast, no significant difference was observed in female patients receiving TP10 in the primary endpoint (28.8% in placebo to 44.7% for TP10; P ϭ 0.96) or in death and MI (17.8 for placebo versus 34% for TP10; P ϭ 0.98). In addition, among the TP10-treated patients, the incidence of death or MI was reduced in male patients undergoing CABG only by 43% in comparison with placebo (12.8% TP10 vs 22.6% placebo; P ϭ 0.043), and the requirement for prolonged intra-aortic balloon pump support in male CABG and valve patients was reduced by 100% (P ϭ 0.019). No improvement was observed in female patients treated with TP10.
In summary, several prospectively randomized placebocontrolled clinical trials involving inhibitors of complement activation have been conducted in patients undergoing CABG surgery, demonstrating some benefit in selected subgroups of patients for attenuating morbidity and mortality. In addition, despite theoretical concerns for an increased risk of infection associated with the antiinflammatory effects of complement inhibitors, the most recent trials involving both pexelizumab and TP10 have not revealed any significant differences in adverse events between treated and placebo groups. Pexelizumab and TP10 did not meet their primary endpoints in their clinical trials, and these biologics are not being further considered for cardiac surgery patients.
One explanation of the marginal positive findings of these clinical studies of complement inhibitors for improving outcomes of patients undergoing cardiac surgery is that they inhibit complement at a late stage of the cascade (e.g., C3/C5 convertase for TP10 and C5 for pexelizumab). As previously discussed, C1INH inhibits C1s and C1s, factors XIIa, XIa, and MASP-1 and MASP-2, [132] [133] [134] [135] and was shown in a clinical study to preserve hemodynamic performance and lower serum troponin levels in comparison with placebo-treated patients undergoing CABG. 139 Thus, C1INH inhibits not only classical and lectin complement cascades, but also the kinin-kallikrien and coagulation systems as well. Along these lines, thrombin is a multifunctional protease with proinflammatory, procoagulant, and proapoptotic effects. 151 Thrombin has direct adverse effects on cardiomyocytes and endothelium and is a major contributor to myocardial ischemia/reperfusion during cardiac surgery. 152 MASP-2 levels are decreased in cardiac surgery patients, and MASP-2 inhibition or depletion is associated with cardioprotection, suggesting that the mannose-binding lectin complex may play an important role in myocardial injury in patients undergoing cardiac surgery. 126, 153 Furthermore, MASP-1 and MASP-2 are involved in coagulation in vitro 154 and recent evidence demonstrates that the mannose-binding lectin complex, and in particular MASP-1, acts like thrombin in vivo. 125 Mannose-binding lectin deficiency in the APEX-AMI clinical trial was associated with significantly reduced mortality at 90 days after primary percutaneous coronary intervention. 155 Additionally, a direct action of mannose-binding lectin on the microvasculature's ability to vasodilate suggests that inhibition of this complement complex should be investigated further for its ability to provide cardioprotection in cardiac surgery patients. 123, 156 In summary, C1INH provides benefits in patients undergoing cardiac surgery. Since C1INH inhibits complement at multiple levels (e.g., C1r/s, MASPs), future clinical studies using C1INH, mannose-binding lectin inhibitors, or inhibitors against the early complement serine proteases (e.g., C1r/s and MASPs) would be warranted.
CONCLUSIONS
Complement was once considered to be a mysterious biochemical pathway involved in a few esoteric diseases. However, the role of complement in inflammatory injury and ischemia/reperfusion injury has recently been extensively studied. In addition, delineation of the complement cascade components, its endogenous regulatory mechanisms, and interactions between different pathways have provided the foundation for developing novel, targeted pharmacological strategies aimed at reducing ischemia/ reperfusion injury and associated morbidity. Several recently published clinical trials involving large numbers of cardiac surgical patients have supported the role of complement inhibition as a therapeutic strategy for improving outcomes of patients susceptible to ischemia/ reperfusion injury. Further investigation will contribute to establishing the role of complement inhibition as a novel target for improving outcomes in cardiac surgical patients.
